Core Insights - Medicus Pharma Ltd. has announced a strategic collaboration with the Gorlin Syndrome Alliance to enhance access to its investigational product SKINJECT™, aimed at treating patients with Gorlin Syndrome [1] Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets [1] Industry Context - Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting approximately 1 in 31,000 people globally, leading to the development of 500-1000 Basal Cell Carcinoma lesions over a lifetime [1]